Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2016

01-09-2016

Male fertility and skin diseases

Authors: M. Badawy Abdel-Naser, Christos C. Zouboulis

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2016

Login to get access

Abstract

Male fertility can be affected by a variety of organs diseases, including the skin. Several genodermatoses affect the skin and several other organs including the male reproductive system, commonly in the form of cryptorchidism and hypogonadism. The most relevant syndromes are associated with dyschromias, such as deSanctis-Cacchione, poikiloderma congenital, LEOPARD, and H syndrome; others with ichthyosis, such as Rud, and trichothiodystrophy; or a group of unrelated genodermatoses, such as ablepharon macrostomia, Coffin-Siris, Gorlin-Goltz, and Werner. Acquired skin diseases may also affect male fertility usually in the form of orchitis or epididymal obstruction or androgen antagonists. These include infections (leprosy and HIV), autoimmune (erythema nodosum leprosum), granulomatous (sarcoidosis, Langerhans cell histiocytosis), nutritional deficiency (zinc), and malignancy. Several therapeutics of skin diseases are notorious for their effects on male fertility, most notably are the cytotoxic drugs (methotrexate), irradiation, and antiandrogens (spironolactone, finasteride). Although the prevalence of these skin diseases is low, the associated male infertility represents a challenge due to the difficulty of its management. Clinical management of the skin diseases should include consideration of their effects not only on the diseases but also on the male reproductive system.
Literature
1.
Koehn FM, Ring J, Schill WB. Dermatologic aspects of male hypogonadism. Hautarzt. 2000;51:223–30.CrossRef
2.
Wirth JJ, Mijal RS. Adverse effects of low level heavy metal exposure on male reproductive function. Syst Biol Reprod Med. 2010;56:147–67.PubMedCrossRef
3.
Sweeney MF, Hasan N, Soto AM, Sonnenschein C. Environmental endocrine disruptors: effects on the human male reproductive system. Rev Endocr Metab Disord. 2015;16:341–57.PubMedPubMedCentralCrossRef
4.
Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab. 1985;60:444–50.PubMedCrossRef
5.
Semple CG, Robertson WR, Mitchell R, Gordon D, Gray CE, Beastall GH, et al. Mechanisms leading to hypogonadism in men with burns injuries. Br Med J. 1987;295:403–7.CrossRef
6.
Dong Q, Hawker F, McWilliam D, Bangah M, Burger H, Handelsman DJ. Circulating immunoreactive inhibin and testosterone levels in men with critical illness. Clin Endocrinol (Oxf). 1992;36:399–404.CrossRef
7.
Eisenberg ML, Li S, Behr B, Pera RR, Cullen MR. Relationship between semen production and medical comorbidity. Fertil Steril. 2015;103:66–71.PubMedCrossRef
8.
Kandeel FR, Swerdloff RS. Role of temperature in regulation of spermatogenesis and the use of heating as a method of contraception. Fertil Steril. 1988;49:1–23.PubMedCrossRef
9.
Handelsman DJ, Staraj S. Testicular size: the effects of aging, malnutrition, and illness. J Androl. 1985;6:144–51.PubMedCrossRef
10.
Li TC, Hindle JE. Adverse local reaction to intramuscular injections of urinary-derived gonadotrophins. Hum Reprod. 1993;8:1835–6.PubMed
11.
Matorras R, Perez C, Corcostegui B, Pijoan JI, Ramon O, Delgado P, et al. Treatment of the male with follicle-stimulating hormone in intrauterine insemination with husband’s spermatozoa: a randomized study. Hum Reprod. 1997;12:24–8.PubMedCrossRef
12.
Jordan Jr WP, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther. 1998;20:80–7.PubMedCrossRef
13.
14.
Berlin CI. Congenital generalized melanoleucoderma associated with hypodontia, hypotrichosis, stunted growth and mental retardation occurring in two brothers and two sisters. Dermatologica. 1961;123:227–43.PubMedCrossRef
15.
Legius E, Daenen W, Vandenbergh V, Verbeeck G, Bex M, Fryns JP. Syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). Genet Couns. 1998;9:287–90.PubMed
16.
Koch CA, Bornstein SR, Chrousos GP, Stratakis CA. Primäre pigmentierte noduläre adrenokortikale Dysplasie (PPNAD) im Rahmen des Carney-Komplexes als Ursache eines Cushing-Syndroms. Med Klin (Munich). 2000;95:224–30.CrossRef
17.
Stratakis CA. Carney complex: a familial lentiginosis predisposing to a variety of tumors. Rev Endocr Metab Disord. 2016. in press.
18.
Wieacker P, Stratakis CA, Horvath A, Klose S, Nickel I, Buhtz P, et al. Male infertility as a component of Carney complex. Andrologia. 2007;39:196–7.PubMedCrossRef
19.
Kirschner LS, Sandrini F, Monbo J, Lin J-P, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet. 2000;9:3037–46.PubMedCrossRef
20.
Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;7:281–93.PubMedPubMedCentral
21.
22.
Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987;123:241–50.PubMedCrossRef
23.
Colella S, Nardo T, Botta E, Lehmann AR, Stefanini M. Identical mutations in the CSB gene associated with either Cockayne syndrome or the DeSanctis-Cacchione variant of xeroderma pigmentosum. Hum Mol Genet. 2000;9:1171–5.PubMedCrossRef
24.
25.
Joenje H, Oostra AB, Wijker M, di Summa FM, van Berkel CG, Rooimans MA, et al. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet. 1997;61:940–4.PubMedPubMedCentralCrossRef
26.
De Kerviler E, Guermazi A, Zagdanski AM, Gluckman E, Frija J. The clinical and radiological features of Fanconi’s anemia. Clin Radiol. 2000;55:340–5.PubMedCrossRef
27.
Fryns JP, Gevers D. Goeminne syndrome (OMIM 314300): another male patient 30 years later. Genet Couns. 2003;14:109–11.PubMed
28.
Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, et al. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010;6:e1000833.PubMedPubMedCentralCrossRef
29.
Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol. 2008;59:79–85.PubMedCrossRef
30.
Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358:592–604.PubMedPubMedCentralCrossRef
31.
32.
Verhagen MMM, Abdo WF, Willemsen MAAP, Hogervorst FBL, Smeets DFCM, Hiel JAP, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology. 2009;73:430–7.PubMedCrossRef
33.
34.
Boyce AM, Chong WH, Shawker TH, Pinto PA, Linehan WM, Bhattacharryya N, et al. Characterization and management of testicular pathology in McCune-Albright syndrome. J Clin Endocrinol Metab. 2012;97:E1782–90.PubMedPubMedCentralCrossRef
35.
Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach Myatonieartigem Zustand im Neugeborenenalter. Schweiz Med Wschr. 1956;86:1260–1.
36.
Bray GA, Dahms WT, Swerdloff RS, Fiser RH, Atkinson RL, Carrel RE. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. Medicine. 1983;62:59–80.PubMedCrossRef
37.
Hamilton Jr CR, Scully RE, Kliman B. Hypogonadotropism in Prader-Willi syndrome: induction of puberty and spermatogenesis by clomiphene citrate. Am J Med. 1972;52:322–9.PubMedCrossRef
38.
Lindor NM, Furuichi Y, Kiato S, et al. Rothman-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom’s and Werner’s syndromes. Am J Med Genet. 2000;90:223.PubMedCrossRef
39.
Venos EM, Collins M, Jane WD. Rothmund-Thomson syndrome: review of the world literature. J Am Acad Dermatol. 1992;27:750.CrossRef
40.
Starr DG, McClure JP, Connor JM. Non-dermatological complications and genetic aspects of the Rothmund-Thomson syndrome. Clin Genet. 1985;27:102–4.PubMedCrossRef
41.
Adachi M, Muroya K, Asakura Y, Kurosawa K, Nishimura G, Narumi S, et al. Ruvalcaba syndrome revisited (letter). Am J Med Genet. 2010;152A:1854–7.PubMedCrossRef
42.
Blyth M, Maloney V, Beal S, Collinson M, Huang S, Crolla J, et al. Pallister-Killian syndrome: a study of 22 British patients. J Med Genet. 2015;52:454–64.PubMedCrossRef
43.
Suryawanshi A, Middleton T, Ganda K. An unusual presentation of X-linked adrenoleukodystrophy. Endocrinol Diabetes Metab Case Rep. 2015;2015:150098.PubMedPubMedCentral
44.
Marxmiller J, Trenkle I, Ashwal S. Rud syndrome revisited: ichthyosis, mental retardation, epilepsy and hypogonadism. Dev Med Child Neurol. 1985;27:335–43.PubMedCrossRef
45.
Stoll C, Eyer D. A syndrome of congenital ichthyosis, hypogonadism, small stature, facial dysmorphism, scoliosis and myogenic dystrophy. Ann Genet. 1999;42:45–50.PubMed
46.
Munke M, Kruse K, Goos M, Ropers HH, Tolksdorf M. Genetic heterogeneity of the ichthyosis, hypogonadism, mental retardation, and epilepsy syndrome: clinical and biochemical investigations on two patients with Rud syndrome and review of the literature. Eur J Pediatr. 1983;141:8–13.PubMedCrossRef
47.
Jorizzo JL, Crounse RG, Wheeler Jr CE. Lamellar ichthyosis, dwarfism, mental retardation, and hair shaft anomalies. J Am Acad Dermatol. 1980;2:309.PubMedCrossRef
48.
Faghri S, Tamura D, Kraemer KH, DiGiovanna JJ. Trichothiodystrophy: a systematic review of 112 published cases characterizes a wide spectrum of clinical manifestations. J Med Genet. 2008;45:609–21.PubMedPubMedCentralCrossRef
49.
Hashimoto S, Egly JM. Trichothiodystrophy view from the molecular basis of DNA repair/transcription factor TFIIH. Hum Mol Genet. 2009;18:R224–30.PubMedCrossRef
50.
Hersh JH, Klein LR, Joyce MR, Hordinsky MK, Tsai MY, Paller A, et al. Trichothiodystrophy and associated anomalies: a variant of SIBIDS or new symptom complex? Pediatr Dermatol. 1993;10:117–22.PubMedCrossRef
51.
52.
Boyle MI, Jespersgaard C, Brondum-Nielsen K, Bisgaard A-M, Tumer Z. Cornelia de Lange syndrome. Clin Genet. 2015;88:1–12.PubMedCrossRef
53.
Vergano SS, Deardorff MA. Clinical features, diagnostic criteria, and management of Coffin-Siris syndrome. Am J Med Genet. 2014;166C:252–6.PubMedCrossRef
54.
Mohrenschlager M, Beham A, Abeck D, Ring J. Atopic eczema in monozygotic twins with Dubowitz syndrome (letter). Br J Dermatol. 1998;138:1091–2.PubMedCrossRef
55.
Pras E, Aksentijevich I, Levy E, Gruberg L, Prosen L, Dean M, et al. The gene causing familial Mediterranean fever maps to the short arm of chromosome 16 in Druze and Moslem Arab families. Hum Genet. 1994;94:576–7.PubMedCrossRef
56.
Mijatovic V, Hompes PG, Wouters MG. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;108:171–6.PubMedCrossRef
57.
Freire-Maia N. A newly recognized genetic syndrome of tetramelic deficiencies, ectodermal dysplasia, deformed ears, and other abnormalities. Am J Hum Genet. 1970;22:370–7.PubMed
58.
Gordon H, Davies D, Berman MM. Camptodactyly, cleft palate and club foot: syndrome showing the autosomal-dominant pattern of inheritance. J Med Genet. 1969;6:266–74.PubMedPubMedCentralCrossRef
59.
Kimonis VE, Singh KE, Zhong R, Pastakia B, DiGiovanna JJ, Bale SJ. Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome. Genet Med. 2013;15:79–83.PubMedCrossRef
60.
61.
Tran TA, Koné-Paut I, Marie I, Ninet J, Cuisset L, Meinzer U. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum. 2012;42:327–31.PubMedCrossRef
62.
Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746–59.PubMedCrossRef
63.
Noonan JA, Raaijmakers R, Hall BD. Adult height in Noonan syndrome. Am J Med Genet. 2003;123A:68–71.PubMedCrossRef
64.
65.
66.
Sagel J, Distiller LA, Morley JE, Isaacs H, Kay G, van der Walt A. Myotonia dystrophica: studies on gonadal function using luteinising-releasing-hormone (LRH). J Clin Endocrinol Metab. 1975;40:1110.PubMedCrossRef
67.
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990–3011.PubMedCrossRef
68.
Goto M, Ishikawa Y, Sugimoto M, Furuichi Y. Werner syndrome: a changing pattern of clinical manifestations in Japan (1917∼2008). Biosci Trends. 2013;7:13–22.PubMed
69.
Epstein CJ, Martin GM, Schultz AL, Motulsky AG. Werner’s syndrome: a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine. 1966;45:177–222.PubMedCrossRef
70.
Tritsch H, Lischka G. Werner’s Syndrom, kombiniert mit Pseudo-Klinefelter syndrom. Hautarzt. 1968;19:547.PubMed
71.
Akhtar M, Ali MA, Mackey DM. Lepromatous leprosy presenting as orchitis. Am J Clin Pathol. 1980;73:72–5.CrossRef
72.
Saporta L, Yuksel A. Androgenic status in patients with lepromatous leprosy. Br J Urol. 1994;74:221–4.PubMedCrossRef
73.
Ghorpade A, Ramanam C. Primary penile tuberculoid leprosy. Indian J Lepr. 2000;72:499–500.PubMed
74.
Parikh DA, Parikh AC, Ganapati R. Penile and scrotal lesions in leprosy: case reports. Lepr Rev. 1989;60:303–5.PubMed
75.
World Health Organization. WHO expert committee on leprosy. Sixth report. In: Tech Rep Ser, vol. 768. Genera: WHO; 1988.
76.
Cheng L, Bostwick DG, editors. Essentials of anatomic pathology. Totowa: Humana Press; 2002.
77.
Brookings C, Goldmeier D, Sadeghi-Nejad H. Sexually transmitted infections and sexual function in relation to male fertility. Korean J Urol. 2013;54:149–56.PubMedPubMedCentralCrossRef
78.
Gorse JG, Belshe RB. Male genital tuberculosis: a review of the literature with instructive case reports. Rev Infect Dis. 1985;7:511–24.PubMedCrossRef
79.
Lewis EL. Tuberculosis of the penis: a report of 5 cases and complete review of the literature. J Urol. 1946;56:737–45.PubMed
80.
81.
De Paepe ME, Waxman M. Testicular atrophy in AIDS: a study of 57 autopsy cases. Hum Pathol. 1989;20:210–4.PubMedCrossRef
82.
Villette JM, Bourin P, Doinel C, Mansour I, Fiet J, Boudou P, et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1990;70:572–7.PubMedCrossRef
83.
Crittenden JA, Handelsman DJ, Stewart GJ. Semen analysis in human immunodeficiency virus infection. Fertil Steril. 1992;57:1294–9.PubMedCrossRef
84.
Nicopoulos JD, Almeida PA, Ramsay JW, Gilling-Smith C. The effect of human immunodeficiency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Hum Reprod. 2004;19:2289–97.CrossRef
85.
Grunert E, Nyfors A, Hansen KB. Studies on human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. Dermatologica. 1977;154:78–84.CrossRef
86.
87.
Sahana PK, Sarma N, Sengupta N, Somani PS. A florid case of iatrogenic Cushing’s syndrome induced by topical steroid with osteoporosis and hypogonadism. Indian J Dermatol. 2015;60:420.PubMedPubMedCentralCrossRef
88.
Hendry WF, Munro DD. “Wash leather scrotum” (scrotal dermatitis): a treatable cause of male infertility. Fertil Steril. 1990;53:379–81.PubMedCrossRef
89.
Van Ahlen H, Hertle L. Disorders of sperm deposition. In: Nieschlag E, Behre HM, editors. Andrology. Berlin: Springer-Verlag; 1997. p. 176.
90.
Hayes FJ, Seminara SB, Crowley Jr WF. Hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am. 1998;27:739–63.PubMedCrossRef
91.
Kovac JR, Flood D, Mullen JB, Fischer MA. Diagnosis and treatment of azoospermia resulting from testicular sarcoidosis. J Androl. 2012;33:162–6.PubMedCrossRef
92.
Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. Q J Med. 2003;96:553–61.CrossRef
93.
Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39:2341–8.PubMedCrossRef
94.
García Gallo MS, Martínez MP, Abalovich MS, Gutiérrez S, Guitelman MA. Endocrine manifestations of Langerhans cell histiocytosis diagnosed in adults. Pituitary. 2010;13:298–303.PubMedCrossRef
95.
Khamseh ME, Mollanai S, Hashemi F, Rezaizadeh A, Azizi F. Erdheim-Chester syndrome, presenting as hypogonadotropic hypogonadism and diabetes insipidus. J Endocrinol Invest. 2002;25:727–9.PubMedCrossRef
96.
Sheu SY, Wenzel RR, Kersting C, Merten R, Otterbach F, Schmid KW. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 2004;57:1225–8.PubMedPubMedCentralCrossRef
97.
Muhammad SS, Epstein JI. Testicular vasculitis: implications of systemic disease. Hum Pathol. 1987;19:186–9.
98.
Jequier AM. Obstruction of the excurrent duct system of the testes. In: Jaquier AM, editor. Male infertility, a clinical guide. 2nd ed. New York: Cambridge University press; 2011. p. 79.CrossRef
99.
Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis. 2004;72:125–33.PubMedCrossRef
100.
Silva CA, Brunner HI. Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus. 2007;16:593–9.PubMedCrossRef
101.
Silva CA, Hallak J, Pasqualotto FF, Barba MF, Saito MI, Kiss MH. Gonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus. J Rheumatol. 2002;29:2000–5.PubMed
102.
Soares PM, Borba EF, Bonfa E, Hallak J, Correa AL, Silva CA. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007;56:2352–61.PubMedCrossRef
103.
Moraes AJP, Pereira RMR, Cocuzza M, Casemiro R, Saito O, Silva CAA. Minor sperm abnormalities in young male post-pubertal patients with juvenile dermatomyositis. Braz J Med Biol Res. 2008;41:1142–7.PubMedCrossRef
104.
Prasad AS. Clinical, endocrinologic, and biochemical effects of zinc deficiency. Spec Top Endocrinol Metab. 1985;7:45–76.PubMed
105.
Zago MP, Oteiza PI. The antioxidant properties of zinc: interactions with iron and antioxidants. Free Radic Biol Med. 2001;31:266–74.PubMedCrossRef
106.
Chimienti F, Aouffen M, Favier A, Seve M. Zinc homeostasis regulating proteins: new drug targets for triggering cell fate. Curr Drug Targets. 2003;4:323–38.PubMedCrossRef
107.
Ebisch IM, Thomas CM, Peters WH, Braat DD, Steegers-Theunissen RP. The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum Reprod Update. 2007;13:163–74.PubMedCrossRef
108.
Hunt CD, Johnson PE, Herbel J, Mullen LK. Effects of dietary zinc depletion on seminal volume and zinc loss, serum testosterone concentrations, and sperm morphology in young men. Am J Clin Nutr. 1992;56:148–57.PubMed
109.
Del Río Prado AF, Reza Albarrán AA, Gómez Pérez FJ. Hombre de 31 años con polineuropatía, postración e hipogonadismo. Gac Med Mex. 2015;151:256–9.PubMed
110.
Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effects of Hodgkin’s disease and combination chemotherapy on gonadal function in adult male. Cancer. 1982;49:418–22.PubMedCrossRef
111.
Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res. 1974;59:665–78.PubMedCrossRef
112.
Meistrich ML, Beek MEAB. Radiation sensitivity of the human testis. Adv Radiat Biol. 1990;14:227–68.CrossRef
113.
da Cuhna MF, Meistrich E, Giusti ML, Fuller LM, Cundiff JH, Hagmeister FB, et al. Recovery of spermatogenesis after treatment for Hodgkin’s disaes: limiting dose of MOPP chemotherapy. J Clin Oncol. 1984;2:571–7.
114.
Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601–5.PubMedCrossRef
115.
ISFP Practice Committee, Kim SS, Donnez J, Barri P, Pellicer A, Patrizio P, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29:465–8.PubMedCentralCrossRef
116.
Handelsman DJ. Testicular dysfunction in systemic diseases. In: Nieschlag E, Behre HM, editors. Andrology. Berlin: Springer-Verlag; 1997. p. 228.
117.
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know? Rev Endocr Metab Disord. 2015;16:177–98.PubMedCrossRef
118.
Şalvarci A, Istanbulluoğlu O. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol. 2013;45:83–5.PubMedCrossRef
119.
Narasimhalu CRV. Randomized questionnaire based case–control research study on evaluation of sexual function in Indian patients taking oral finasteride for androgenetic alopecia. Dermatol Ther (Heidelb). 2015;5:231–4.CrossRef
120.
Qian SZ, Hu YZ, Wang SM, Luo Y, Tang AS, Shu SY, et al. Effects of Tripterygium hypoglaucum (Lévl.) Hutch on male fertility. Adv Contracept. 1988;4:307–10.PubMedCrossRef
121.
Ilani N, Swerdloff RS, Wang C. Male hormonal contraception: potential risks and benefits. Rev Endocr Metab Disord. 2011;12:107–17.PubMedCrossRef
122.
Chao JH, Page ST. The current state of male hormonal contraception. Pharmacol Ther. 2016;163:109–17.PubMedCrossRef
Metadata
Title
Male fertility and skin diseases
Authors
M. Badawy Abdel-Naser
Christos C. Zouboulis
Publication date
01-09-2016
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2016
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9368-x

Other articles of this Issue 3/2016

Reviews in Endocrine and Metabolic Disorders 3/2016 Go to the issue

ReviewPaper

Skin manifestations of Cushing’s syndrome

ReviewPaper

Endocrine-disrupting chemicals and skin manifestations

ReviewPaper

Skin steroidogenesis in health and disease

ReviewPaper

Flushing in (neuro)endocrinology

ReviewPaper

Beyond acne: Current aspects of sebaceous gland biology and function

ReviewPaper

Carney complex: A familial lentiginosis predisposing to a variety of tumors
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits